This site is intended for health professionals only

Published on 17 June 2013

Share this story:
Twitter
LinkedIn

RAPID™-PsA study highlights burden of psoriatic arthritis

teaser

UCB has announced new data from the RAPIDTM-PsA study on certolizumab pegol in the treatment of moderate to severe psoriatic arthritis (PsA) at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain. Results showed that certolizumab pegol improved multiple patient reported outcomes including pain, fatigue and health-related quality of life.(1)
Patients reported that PsA placed a high burden of disease on workplace and household productivity. Compared with the placebo group, patients treated with certolizumab pegol reported improvements in productivity at the workplace through reduced absenteeism, presenteeism and PsA interference with work, as well as improvements in household productivity and increased participation in social and daily activities.(2,3)
“PsA places a high burden of disease on paid work and household activity that in turn could lead to a financial burden for both patients and society,” said Professor Dafna Gladman, Toronto Western Research Institute, Canada. “To date, there are few data on work and household productivity among patients with PsA. The RAPID™-PsA study offers additional insight on the burden of PsA. In this study, patients treated with certolizumab pegol reported improved work and household productivity as well as improvements in outcomes such as fatigue and pain, which can help patients cope with everyday activities.”
PsA is a chronic inflammatory condition which affects both the skin and joints.(4) The RAPIDTM-PsA study is an ongoing Phase 3, multicentre, randomised, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of certolizumab pegol in patients with adult onset active and progressive PsA. Patients (n=409) were randomised 1:1:1 to placebo, or 400mg certolizumab pegol at week 0, 2 and 4 loading dose followed by either 200 mg certolizumab pegol every two weeks or 400mg certolizumab pegol every four weeks.(5) The clinical primary endpoint of the RAPID™-PsA study was the ACR20 response at week 12. The ACR20 response at week 12 was significantly higher in both the certolizumab pegol arms of the study vs. placebo (p<0.001). Adverse events occurred in 62% versus 68% and serious adverse events in 7% versus 4% in certolizumab pegol (combined dose) versus placebo, respectively.(6)
References
  1. Gladman D., Fleischmann R., Coteur G. et al. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients with and without prior anti-TNF exposure: 24-week patient reported outcome results of RAPID-PsA study. Presented at the European League Against Rheumatism (EULAR) 2013 Congress. Abstract # SAT0260
  2. Kavanaugh A., Mease J.P., Purcaru O. et al. High economic burden of moderate to severe psoriatic arthritis on paid work and household productivity: Baseline results from the RAPID-PsA study. Presented at the European League Against Rheumatism (EULAR) 2013 Congress. Abstract # SAT0275
  3. Kavanaugh A., Gladman D., Van der Heijde D., Braun J. et al. Improvements in productivity at paid work and within household and increased participation in daily activities after 24 weeks of certolizumab pegol in patients with psoriatic arthritis: Results of RAPID-PsA study. Presented at the European League Against Rheumatism (EULAR) 2013 Congress. Abstract # SAT0276
  4. Psoriatic Arthritis, Genetics Home Reference. Accessed 10th June, 2013 from http://ghr.nlm.nih.gov/condition/psoriatic-arthritis
  5. 5. ClinTrials.gov. Certolizumab pegol in subjects with adult onset active and progressive psoriatic arthritis. Accessed 10th June, 2013 from http://www.clinicaltrials.gov/ct2/show/NCT01087788?term=certolizumab+pegol+and+psoriatic+arthritis&rank=1
  6. Mease P.J., Fleischmann R., Wollenhaupt J. et al. Effect if certolizumab pegol on signs and symptoms in patients with psoriatic arthritis from the RAPID-PsA study: Impact of baseline skin involvement and prior anti-TNF therapy. Presented at the European League Against Rheumatism (EULAR) 2013 Congress. Abstract # SAT0298


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn